Rhumbline Advisers Adma Biologics, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 652,558 shares of ADMA stock, worth $9.54 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

652,558

Previous 622,167 4.88%

Holding current value

$9.54 Million

Previous $12.3 Million 3.73%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$17.6 - $24.51 $534,881 - $744,883	30,391 Added 4.88%	652,558 $11.9 Million
Q1 2025 Apr 08, 2025	BUY	$15.44 - $20.61 $16,798 - $22,423	1,088 Added 0.18%	622,167 $12.6 Million
Q4 2024 May 29, 2025	SELL	$15.62 - $22.62 $16,994 - $24,610	-1,088 Reduced 0.17%	621,079 $10.7 Million
Q4 2024 Jan 30, 2025	BUY	$15.62 - $22.62 $91,861 - $133,028	5,881 Added 0.96%	621,079 $10.7 Million
Q3 2024 Nov 12, 2024	BUY	$11.21 - $20.03 $3.42 Million - $6.1 Million	304,659 Added 98.11%	615,198 $12.3 Million
Q2 2024 Aug 01, 2024	BUY	$5.98 - $11.18 $94,747 - $177,135	15,844 Added 5.38%	310,539 $3.47 Million
Q1 2024 May 09, 2024	BUY	$4.4 - $6.74 $27,931 - $42,785	6,348 Added 2.2%	294,695 $1.94 Million
Q4 2023 Feb 08, 2024	BUY	$3.08 - $4.52 $1,900 - $2,788	617 Added 0.21%	288,347 $1.3 Million
Q3 2023 Nov 09, 2023	BUY	$3.47 - $4.61 $28,127 - $37,368	8,106 Added 2.9%	287,730 $1.03 Million
Q2 2023 Aug 08, 2023	SELL	$3.12 - $4.22 $11,690 - $15,812	-3,747 Reduced 1.32%	279,624 $1.03 Million
Q1 2023 May 11, 2023	BUY	$3.01 - $3.87 $101,665 - $130,713	33,776 Added 13.53%	283,371 $938,000
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $7,414 - $11,647	3,002 Added 1.22%	249,595 $968,000
Q3 2022 Nov 10, 2022	BUY	$2.03 - $2.86 $31,422 - $44,269	15,479 Added 6.7%	246,593 $599,000
Q2 2022 Aug 11, 2022	BUY	$1.43 - $2.2 $330,493 - $508,450	231,114 New	231,114 $458,000
Q2 2021 Aug 05, 2021	SELL	$1.51 - $2.07 $97,693 - $133,924	-64,698 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$1.67 - $2.95 $167 - $295	100 Added 0.15%	64,698 $114,000
Q4 2020 Feb 10, 2021	BUY	$1.8 - $2.56 $10,850 - $15,431	6,028 Added 10.29%	64,598 $126,000
Q3 2020 Nov 12, 2020	SELL	$2.04 - $3.74 $22,040 - $40,406	-10,804 Reduced 15.57%	58,570 $140,000
Q2 2020 Aug 13, 2020	BUY	$2.42 - $3.29 $49,854 - $67,777	20,601 Added 42.24%	69,374 $203,000
Q1 2020 May 06, 2020	BUY	$1.5 - $4.59 $3,613 - $11,057	2,409 Added 5.2%	48,773 $140,000
Q4 2019 Feb 05, 2020	BUY	$3.89 - $5.15 $2,034 - $2,693	523 Added 1.14%	46,364 $185,000
Q3 2019 Oct 23, 2019	BUY	$3.19 - $5.39 $52,453 - $88,627	16,443 Added 55.93%	45,841 $204,000
Q2 2019 Aug 14, 2019	BUY	$3.52 - $5.24 $23,228 - $34,578	6,599 Added 28.94%	29,398 $114,000
Q1 2019 May 01, 2019	SELL	$2.61 - $4.35 $1,252 - $2,088	-480 Reduced 2.06%	22,799 $86,000
Q4 2018 Jan 31, 2019	BUY	$2.17 - $6.12 $16,947 - $47,797	7,810 Added 50.49%	23,279 $56,000
Q3 2018 Nov 07, 2018	SELL	$4.39 - $6.85 $2,594 - $4,048	-591 Reduced 3.68%	15,469 $96,000
Q2 2018 Aug 06, 2018	BUY	$4.39 - $5.44 $70,503 - $87,366	16,060 New	16,060 $72,000

Others Institutions Holding ADMA

# of Institutions

400

Shares Held

197M

Call Options Held

2.08M

Put Options Held

1.56M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $2.87B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Adma Biologics, Inc. Transaction History